| Literature DB >> 25761994 |
Emi Tateishi1, Teruo Noguchi2, Yoichi Goto2, Yoshiaki Morita3, Hatsue Ishibashi-Ueda4, Naoaki Yamada3, Hideaki Kanzaki2, Kunihiro Nishimura5, Yoshihiro Miyamoto5, Toshihisa Anzai2, Hisao Ogawa6, Satoshi Yasuda1.
Abstract
OBJECTIVE: Late gadolinium enhancement (LGE) is not necessarily ideal for detecting diffuse myocardial fibrosis in idiopathic dilated cardiomyopathy (DCM). Since systolic blood pressure response (SBPR) during exercise has been proposed to reflect cardiac pump reserve in patients with heart failure, we wished to determine whether LGE plus SBPR is a better prognostic factor in patients with DCM.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25761994 PMCID: PMC4431328 DOI: 10.1136/heartjnl-2014-307007
Source DB: PubMed Journal: Heart ISSN: 1355-6037 Impact factor: 5.994
Figure 1Representative examples of short-axis LGE-positive and LGE-negative images. A, B and C are short-axis images from LGE-positive patients. The typical LGE pattern in DCM is mid-wall enhancement in the interventricular septum (A). A diffuse pattern was observed in 34 out of 105 LGE-positive patients (B). Nineteen patients had focal enhancement (C, arrow). Figure 1D is a representative example of a LGE-negative case. DCM, dilated cardiomyopathy; LGE, late gadolinium enhancement.
Figure 2Receiver operating characteristics (ROC) curve analysis for the development of cardiac events and flow chart of study patients on the basis of LGE and SBPR. (A) ROC curve to determine the optimal cut-off value of SBPR for cardiac events. (B) Flow diagram illustrating the number of participants. DCM, dilated cardiomyopathy; LGE, late gadolinium enhancement; ROC, receiver operator characteristics; SBPR, systolic blood pressure response.
Characteristics of the study patients
| All patients (n=207) | LGE-positive | LGE-negative | p Value | |||
|---|---|---|---|---|---|---|
| SBPR <40 mm Hg (n=65) | SBPR ≥40 mm Hg (n=40) | SBPR <40 mm Hg (n=33) | SBPR ≥40 mm Hg (n=69) | |||
| Age (years) | 50±16 | 54±16 | 52±13 | 51±16 | 45±16 | 0.004 |
| Male | 165 (80) | 50 (77) | 37 (93) | 24 (73) | 54 (78) | 0.096 |
| NYHA functional class | 0.009 | |||||
| I | 58 (28) | 15 (23) | 14 (35) | 3 (9) | 26 (38) | |
| II | 58 (28) | 23 (35) | 10 (25) | 13 (39) | 12 (17) | |
| III | 26 (13) | 10 (15) | 5 (13) | 7 (21) | 4 (6) | |
| VI | 65 (31) | 17 (26) | 11 (28) | 10 (30) | 27 (39) | |
| Hypertension | 76 (37) | 23 (35) | 16 (40) | 6 (18) | 31 (45) | 0.055 |
| Atrial fibrillation | 51 (25) | 13 (20) | 13 (33) | 9 (27) | 16 (23) | 0.178 |
| History of VT/Vf | 8 (4) | 6 (9) | 0 | 2 (6) | 0 | 0.006 |
| BNP (mg/dL) | 93 (38–213) | 170 (72–404) | 93 (40–176) | 131 (39–252) | 50 (13–108) | <0.001 |
| Creatine (mg/dL) | 0.85±0.23 | 0.85±0.23 | 0.81±0.20 | 0.91±0.19 | 0.85±0.25 | 0.377 |
| ECG parameters | ||||||
| QRS duration (ms) | 117±30 | 125±37 | 115±21 | 119±28 | 109±25 | 0.023 |
| QTc interval (ms) | 437±53 | 452±43 | 430±66 | 442±59 | 424±45 | 0.015 |
| Medications | ||||||
| β-blocker | 196 (95) | 65 (100) | 37 (93) | 31 (94) | 63 (91) | 0.032 |
| ACE-I/ARB | 173 (84) | 60 (92) | 31 (78) | 26 (79) | 56 (81) | 0.106 |
| Aldosterone antagonist | 86 (42) | 37 (57) | 14 (35) | 14 (42) | 21 (30) | 0.014 |
| Loop diuretics | 120 (58) | 37 (57) | 14 (35) | 14 (42) | 21 (30) | 0.009 |
| Digoxin | 41 (20) | 15 (23) | 6 (15) | 10 (30) | 10 (14) | 0.220 |
| Amiodarone | 22 (11) | 14 (22) | 4 (10) | 2 (6) | 2 (3) | 0.004 |
| Exercise testing | ||||||
| HR at rest (beats/min) | 79±15 | 77±14 | 74±15 | 84±12 | 80±16 | 0.029 |
| SBP at rest (mm Hg) | 114±18 | 112±20 | 111±16 | 111±18 | 118±17 | 0.151 |
| Peak SBP (mm Hg) | 157±31 | 135±22 | 168±24 | 135±22 | 181±24 | <0.001 |
| Peak VO2 (mL/min/kg) | 22±6 | 19±5 | 23±5 | 20±5 | 25±7 | <0.001 |
| VE/VCO2 slope | 29±6 | 31±7 | 28±5 | 31±8 | 26±4 | <0.001 |
| CMR parameters | ||||||
| LVEF (%) | 27±11 | 24±10 | 25±11 | 23±10 | 32±10 | <0.001 |
| LVEDVI (mL/m2) | 143±57 | 161±64 | 152±54 | 153±66 | 117±34 | <0.001 |
| LVESVI (mL/m2) | 109±56 | 126±63 | 117±51 | 123±66 | 81±33 | <0.001 |
| LV mass (g) | 149±49 | 149±6 | 162±8 | 142±9 | 147±6 | 0.296 |
| RVEF (%) | 36±10 | 35±10 | 37±10 | 35±11 | 38±10 | 0.351 |
Values are means±SD, n (%), or median (first quartile, third quartile).
ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; CMR, cardiac magnetic resonance; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; HR, heart rate; LGE, late gadolinium enhancement; NYHA, New York Heart Association; peak VO2, peak oxygen uptake; SBP, systolic blood pressure; SBPR, systolic blood pressure response; VE/VCO2 slope, regression slope relating minute ventilation to carbon dioxide output; Vf, ventricular fibrillation; VT, ventricular tachycardia.
Incidence of cardiac events during follow-up
| All patients (n=207) | LGE-positive | LGE-negative | p Value | |||
|---|---|---|---|---|---|---|
| SBPR <40 mm Hg (n=65) | SBPR ≥40 mm Hg (n=40) | SBPR <40 mm Hg (n=33) | SBPR ≥40 mm Hg (n=69) | |||
| All cardiac events | 42 (20) | 23 (35) | 8 (20) | 7 (21) | 4 (6) | <0.001 |
| Cardiac death | 4 (2) | 4 (6) | 0 | 0 | 0 | 0.024 |
| Cardiac transplantation | 1 (0.5) | 1 (2) | 0 | 0 | 0 | 0.507 |
| LVAD implantation | 3 (1) | 0 | 1 (3) | 2 (6) | 0 | 0.075 |
| ICD discharge for VT/Vf | 7 (3) | 3 (5) | 2 (5) | 2 (6) | 0 | 0.117 |
| Rehospitalisation for HF | 27 (13) | 15 (23) | 5 (13) | 3 (9) | 4 (6) | 0.026 |
Values are numbers (%).
HF, heart failure; ICD, implantable cardioverter-defibrillator; LVAD, LV assist device; SBPR, systolic blood pressure response; Vf, ventricular fibrillation; VT, ventricular tachycardia.
Figure 3Kaplan-Meier curves comparing the probability of all cardiac events. The LGE-positive+SBPR <40 mm Hg group had the worst prognosis. Importantly, the all cardiac event rate in the LGE-negative+SBPR <40 mm Hg group was intermediate, but comparable with the rate in the LGE-positive+SBPR ≥40 mm Hg group (p=0.736). LGE, late gadolinium enhancement; SBPR, systolic blood pressure response.
Univariable Cox regression analysis of risk factors for all cardiac events
| HR | 95% CI | p Value | |
|---|---|---|---|
| Age (per 5 years) | 1.02 | 0.92 to 1.12 | 0.821 |
| Male | 1.27 | 0.60 to 3.10 | 0.563 |
| NYHA class on admission | 1.17 | 0.91 to 1.52 | 0.222 |
| Hypertension | 0.58 | 0.28 to 1.12 | 0.105 |
| Atrial fibrillation | 1.42 | 0.71 to 2.67 | 0.308 |
| History of VT/Vf | 5.16 | 1.93 to 11.6 | 0.002 |
| BNP (per 10 mg/dL increments) | 1.02 | 1.01 to 1.02 | 0.001 |
| Creatine | 3.65 | 1.05 to 11.0 | 0.042 |
| ECG parameters | |||
| QRS duration (per 10 ms increments) | 1.12 | 1.02 to 1.22 | 0.022 |
| QTc interval (per 10 ms increments) | 1.11 | 1.04 to 1.18 | 0.003 |
| Exercise testing | |||
| Heart rate at rest (per 10 bpm increments) | 0.81 | 0.66 to 1.00 | 0.048 |
| SBP at rest (per 10 mm Hg increments) | 0.75 | 0.62 to 0.90 | 0.002 |
| SBPR <40 mm Hg | 3.31 | 1.74 to 6.75 | <0.001 |
| Peak VO2 (per 1 mL/min/kg decrement) | 1.04 | 0.98 to 1.10 | 0.134 |
| VE/VCO2 slope | 1.01 | 0.95 to 1.06 | 0.724 |
| CMR parameters | |||
| LVEF (per 10% decrements) | 1.60 | 1.18 to 2.21 | 0.002 |
| LVEDVI (per 10 mL/m2 increments) | 1.01 | 1.06 to 1.14 | <0.001 |
| LVESVI (per 10 mL/m2 increments) | 1.11 | 1.06 to 1.15 | <0.001 |
| LV mass | 0.99 | 0.99 to 1.00 | 0.99 |
| RVEF (per 10% decrements) | 1.18 | 0.89 to 1.56 | 0.251 |
| Presence of LGE | 3.00 | 1.55 to 6.25 | 0.001 |
BNP, brain natriuretic peptide; CMR, cardiac magnetic resonance; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; LGE, late gadolinium enhancement; NYHA, New York Heart Association; peak VO2, peak oxygen uptake; SBP, systolic blood pressure; SBPR, systolic blood pressure response; VE/VCO2 slope, regression slope relating minute ventilation to carbon dioxide output; Vf, ventricular fibrillation; VT, ventricular tachycardia.
Multivariable Cox regression analysis of risk factors for all cardiac events
| Model 1* | Model 2† | Model 3‡ | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p Value | HR | 95% CI | p Value | HR | 95% CI | p Value | |
| History of VT/Vf | 3.16 | 1.26 to 7.89 | 0.014 | 2.83 | 1.03 to 6.67 | 0.044 | 2.96 | 1.06 to 6.98 | 0.037 |
| QTc interval (per 10 ms increments) | 1.01 | 1.00 to 1.01 | 0.063 | 1.04 | 0.97 to 1.11 | 0.324 | 1.04 | 0.97 to 1.12 | 0.270 |
| LVEDVI (per 10 mL/m2 increments) | 1.01 | 1.00 to 1.01 | 0.001 | 1.07 | 1.02 to 1.12 | 0.004 | 1.08 | 1.03 to 1.12 | 0.012 |
| Presence of LGE | 1.96 | 1.01 to 3.78 | 0.046 | ||||||
| SBPR <40 mm Hg | 1.93 | 1.02 to 3.65 | 0.042 | ||||||
| LGE-negative+SBPR <40 mm Hg | 2.62 | 0.77 to 10.19 | 0.122 | ||||||
| LGE-positive+SBPR ≥40 mm Hg | 2.26 | 0.69 to 8.65 | 0.179 | ||||||
| LGE-positive+SBPR <40 mm Hg | 4.05 | 1.41 to 14.55 | 0.008 | 2.08 | 1.06 to 4.11 | 0.034 | |||
*Multivariable Cox model selected by a stepwise method with factors that were significant in the univariable analysis and established risk factors for prognosis (age, gender, NYHA class, peak VO2, VE/VCO2 slope).
†Model with the combination of LGE and SBPR, adjusted for predictors selected by Model 1.
‡Best predictive model, adjusted for significant predictors selected by a stepwise Cox regression analysis based on Models 1 and 2.
EDVI, end-diastolic volume index; LGE, late gadolinium enhancement; NYHA, New York Heart Association; peak VO2, peak oxygen uptake; SBPR, systolic blood pressure response; VE/VCO2 slope, regression slope relating minute ventilation to carbon dioxide output; Vf, ventricular fibrillation; VT, ventricular tachycardia.